compassionate grounds
New FDA expanded access guidelines spell trouble for Sarepta
June 2, 2016Medical Communications, Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, Eteplirsen, FDA, compassionate grounds, sarepta
New guidelines intended to streamline the process of expanded access to medicines by the US Food and Drug Administration (FDA) …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
